Evidence map›Paper›PMID 30208932›Full record

ArticleBreast cancer research : BCR2018

Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells.

Pin Gao, Xiang Wang, Ying Jin, Wenquan Hu, Yajun Duan, Aiping Shi, Ye Du, Dong Song, Ming Yang, Sijie Li and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Research advances on neurite outgrowth inhibitor B receptor.Journal of cellular and molecular medicine · 2020
    Review
  8. Article
  9. Chitosan-Based Nanomaterials for Drug Delivery.Molecules (Basel, Switzerland) · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 3 countries.

Pin GaoDepartment of Breast Surgery, The First Hospital of Jilin University, 71 Xinmin street, Changchun, 130021, Jilin Province, China.
Xiang WangDivision of Pediatric Surgery, Department of Surgery, Children's Research Institute, Medical College of Wisconsin, 8701 W Watertown Plank Rd, Milwaukee, WI, 53226, USA.
Ying JinDepartment of Breast Surgery, The First Hospital of Jilin University, 71 Xinmin street, Changchun, 130021, Jilin Province, China.
Wenquan HuDivision of Pediatric Surgery, Department of Surgery, Children's Research Institute, Medical College of Wisconsin, 8701 W Watertown Plank Rd, Milwaukee, WI, 53226, USA.
Yajun DuanDivision of Pediatric Surgery, Department of Surgery, Children's Research Institute, Medical College of Wisconsin, 8701 W Watertown Plank Rd, Milwaukee, WI, 53226, USA.
Aiping ShiDepartment of Breast Surgery, The First Hospital of Jilin University, 71 Xinmin street, Changchun, 130021, Jilin Province, China.
Ye DuDepartment of Breast Surgery, The First Hospital of Jilin University, 71 Xinmin street, Changchun, 130021, Jilin Province, China.
Dong SongDepartment of Breast Surgery, The First Hospital of Jilin University, 71 Xinmin street, Changchun, 130021, Jilin Province, China.
Ming YangDepartment of Breast Surgery, The First Hospital of Jilin University, 71 Xinmin street, Changchun, 130021, Jilin Province, China.
Sijie LiDepartment of Breast Surgery, The First Hospital of Jilin University, 71 Xinmin street, Changchun, 130021, Jilin Province, China.
Bing HanDepartment of Breast Surgery, The First Hospital of Jilin University, 71 Xinmin street, Changchun, 130021, Jilin Province, China.
Gang ZhaoDepartment of Breast Surgery, The First Hospital of Jilin University, 71 Xinmin street, Changchun, 130021, Jilin Province, China.
Hongquan ZhangDepartment of Human Anatomy, Histology, and Embryology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) and State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Beijing, 100191, China. hongquan.zhang@bjmu.edu.cn.
Zhimin FanDepartment of Breast Surgery, The First Hospital of Jilin University, 71 Xinmin street, Changchun, 130021, Jilin Province, China. fanzhimn@163.com.
Qing Robert MiaoDivision of Pediatric Surgery, Department of Surgery, Children's Research Institute, Medical College of Wisconsin, 8701 W Watertown Plank Rd, Milwaukee, WI, 53226, USA. qmiao@mcw.edu.ORCID 0000-0002-3125-1238
Jilin University · CNChildren's Hospital of Wisconsin · USMinistry of Education of the People's Republic of China · CN

Funding

Role of NgBR in Hepatic SteatosisR01DK112971 · NIDDK · NYU WINTHROP HOSPITAL · PI MIAO, QING · 2017 to 2021
$2.1M
Role of NgBRR01HL108938 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI MIAO, QING · 2011 to 2015
$1.8M
NHLBI NIH HHS R01 HL108938NIDDK NIH HHS R01 DK112971
6 · The paper itself

Abstract

backgroundsTamoxifen is typically used to treat patients with estrogen receptor alpha (ERα)-positive breast cancer. However, 30% of these patients gain acquired resistance to tamoxifen during or after tamoxifen treatment. As a Ras modulator, Nogo-B receptor (NgBR) is required for tumorigenesis through the signaling crosstalk with epidermal growth factor (EGF) receptor (EGFR)-mediated pathways. NgBR is highly expressed in many types of cancer cells and regulates the sensitivity of hepatocellular carcinoma to chemotherapy. In this study, we found the expression of NgBR is increased in tamoxifen-resistant ERα-positive breast cancer cells.

methodsTamoxifen-resistant ERα-positive MCF-7 and T47D breast cancer cell lines were established by culturing with gradually increased concentration of 4-hydroxytamoxifen (4-OHT). The effects of NgBR on tamoxifen resistance was determined by depleting NgBR in these cell lines using previously validated small interfering RNA (siRNA). The effects of 4-OHT on cell viability and apoptosis were determined using well-accepted methods such as clonogenic survival assay and Annexin V/propidium iodide staining. The alteration of EGF-stimulated signaling and gene expression was determined by western blot analysis and real-time PCR, respectively.

resultsNgBR knockdown with siRNA attenuates EGF-induced phosphorylation of ERα and restores the sensitivity to tamoxifen in ERα-positive breast cancer cells. Mechanistically, our data demonstrated that NgBR knockdown increases the protein levels of p53 and decreases survivin, which is an apoptosis inhibitor.

conclusionsThese results suggested that NgBR is a potential therapeutic target for increasing the sensitivity of ERα-positive breast cancer to tamoxifen.

Indexed as

Antineoplastic Agents, HormonalApoptosisBreast NeoplasmsCell Line, TumorDrug Resistance, NeoplasmEpidermal Growth FactorEstrogen Receptor alphaFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMCF-7 CellsPhosphorylationReceptors, Cell SurfaceRNA InterferenceAntineoplastic Agents, HormonalEpidermal Growth FactorESR1 protein, humanEstrogen Receptor alphaNUS1 protein, humanReceptors, Cell SurfaceSurvivinTamoxifenTumor Suppressor Protein p53Breast cancerEstrogen receptorNogo-B receptorSurvivinTamoxifen

Identifiers

PMID30208932
PMCPMC6134690
OpenAlexW2891360563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.